Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioNTech SE

Market Cap 19.51B 22.63B 17.96B 16.86B 31.66B 2,140B 32B 212B 82.68B 1,048B 84.94B 83.14B 3,632B P/E Ratio 2026 *
-17.5x
P/E Ratio 2027 * -17.2x
Enterprise Value 8.65B 10.04B 7.97B 7.48B 14.05B 949B 14.19B 94.15B 36.68B 465B 37.68B 36.88B 1,611B EV / Sales 2026 *
4x
EV / Sales 2027 * 4.58x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 week+3.34%
Current month-5.90%
1 month-0.06%
3 months-1.65%
6 months-1.71%
Current year-4.80%
1 week 73.2
Extreme 73.2
79.55
1 month 73.2
Extreme 73.2
84.9
3 years 68.35
Extreme 68.35
124.7
5 years 68.35
Extreme 68.35
397
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+3.34%-16.05%-24.85% 22.63B
+1.27%+0.31%+61.89%+112.55% 54.54B
-1.22%+5.01%+43.38%+36.69% 43.86B
-1.99%-3.55%-5.97%+377.60% 20.7B
-0.53%+0.54%+16.19%-36.06% 15.84B
+3.05%-0.03%+11.55%-39.16% 14.83B
-1.70%-1.68%+24.79%+172.92% 13.1B
-5.17%+0.50%+21.80% - 12.66B
+0.29%+5.10%+75.82%+105.33% 11.56B
+4.10%+0.10%+108.68%+226.33% 11.68B
Average -0.21%-0.15%+34.21%+103.48% 22.08B
Weighted average by Cap. -0.13%-0.18%+35.97%+95.70%

Financials

2026 *2027 *
Net sales 2.17B 2.51B 1.99B 1.87B 3.52B 238B 3.55B 23.57B 9.18B 116B 9.43B 9.23B 403B 2.23B 2.59B 2.05B 1.93B 3.62B 245B 3.66B 24.27B 9.46B 120B 9.71B 9.51B 415B
Net income -1.05B -1.22B -968M -909M -1.71B -115B -1.72B -11.43B -4.45B -56.46B -4.58B -4.48B -196B -1.17B -1.35B -1.07B -1.01B -1.89B -128B -1.91B -12.68B -4.94B -62.61B -5.07B -4.97B -217B
Net Debt -10.85B -12.59B -9.99B -9.38B -17.62B -1,191B -17.8B -118B -46B -583B -47.26B -46.25B -2,020B -9.28B -10.77B -8.55B -8.02B -15.07B -1,018B -15.22B -101B -39.34B -499B -40.42B -39.56B -1,728B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Date Price Change
17/06/26 78.00 +0.78%
16/06/26 77.40 -1.34%
15/06/26 78.45 +0.71%
12/06/26 77.90 +0.84%
11/06/26 77.25 +3.07%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
77.13EUR
Average target price
106.75EUR
Spread / Average Target
+38.41%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!